Summary & Overview
HCPCS J0282: Amiodarone Hydrochloride Injection, 30 mg
HCPCS Level II code J0282 denotes a 30 mg injectable dose of amiodarone hydrochloride, an antiarrhythmic medication used in acute care for certain life‑threatening cardiac arrhythmias. Nationally, accurate coding and billing of parenteral antiarrhythmic agents matter for clinical documentation, hospital pharmacy inventory management, and payer reimbursement consistency across inpatient and emergency settings.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of coding intent and clinical context, typical sites of service where J0282 is used, and what to expect in payer coverage patterns. The publication outlines common billing considerations, benchmark concepts, and relevant policy updates that affect how injectable amiodarone is processed on claims.
The report is designed to support billing managers, clinical coders, and pharmacy revenue teams by clarifying the code’s clinical application and situational use. Where available, benchmarking information and payer policy summaries are presented to illustrate differences in coverage approaches. Data not available in the input is identified as such and omitted from specific quantitative sections.
Billing Code Overview
HCPCS Level II code J0282 represents an injection of amiodarone hydrochloride, 30 mg. This entry describes a single-dose injectable formulation of the antiarrhythmic medication amiodarone, used in acute management of certain cardiac arrhythmias.
-
Service type: Medication administration (intravenous injection)
-
Typical site of service: Hospital inpatient, emergency department, and other acute care settings where intravenous antiarrhythmic therapy is administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 68-year-old male with a history of ischemic cardiomyopathy and recurrent sustained ventricular tachycardia is admitted to the cardiac intensive care unit for arrhythmia management. He is hemodynamically stable but continues to have symptomatic, recurrent ventricular ectopy and non-sustained ventricular tachycardia despite rate control and beta-blocker therapy. Intravenous antiarrhythmic therapy is initiated with a dose of amiodarone delivered as an intravenous injection formulation. The typical clinical workflow includes medication order entry by the cardiology team, pharmacy verification and preparation of J0282 (Injection, amiodarone hydrochloride, 30 mg), nursing administration via slow IV push or infusion per protocol, continuous cardiac monitoring during and after administration, documentation of dose, route, lot number or applicable modifier (e.g., JW for discarded drug), and reassessment of rhythm and hemodynamics. Typical sites of service include the emergency department, hospital inpatient ward, telemetry unit, and intensive care unit.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug/biological amount discarded | Use when a portion of a single-dose vial of amiodarone is discarded and payer requires reporting of discarded drug. |